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Abstract 
Somatostatin analogs (SSA) with their potent antisecretory and antiproliferative effects are the main medical 
treatment option for patients with neuroendocrine tumors, such as gastroenteropancreatic and acromegaly-
associated growth hormone secreting pituitary tumors. Although a good portion of acromegalic patients gets 
normalized after SSA treatment, strict hormonal control is not achieved in a sizeable proportion of these patients. 
The reasons for this incomplete response to SSA treatment are unclear. We have found that the tumor suppressor 
ZAC1 (LOT1/PLAGL1) is essential for the antiproliferative effect of SSA in pituitary tumor cells. The aim of 
the present retrospective cohort study was to determine whether ZAC1 immunoreactivity in archival 
somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with SSA before 
surgery, was associated with response to SSA (normalization of GH, IGF-I and presence of tumor shrinkage). 
All tumors displayed ZAC1 immunoreactivity [weak (+ ; n = 15), moderate (+ + ; n = 16) and strong (+ + + ; n 
= 14)]. A significant positive correlation was found between strong ZAC1 immunoreactivity and IGF-I 
normalization and presence of tumor shrinkage after SSA treatment, which was not affected by age at diagnosis, 
gender or duration of SSA treatment. These in vivo data combined with the antiproliferative properties of 
ZAC1/Zac1 provide evidence of a mechanistic role for this transcription factor on SSA induced tumor shrinkage 
and hormone normalization. 
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The potent antisecretory and antiproliferative effects of somatostatin have made it a target for vigorous research 
for drug discovery.1 Somatostatin analogues (SSA) are widely used to control hormone secretion and tumor 
growth in various neuroendocrine tumors including gastroenteropancreatic and GH secreting pituitary tumors. 
Patients with GH secreting pituitary adenomas (somatotrophinomas) present with acromegaly, a syndrome 
caused by chronic GH hypersecretion and subsequent increase in IGF-I levels and characterized by overgrowth 
of the extremities, cardiac dysfunction, hypertension and metabolic disturbances.2 Acromegaly is associated with 
increased mortality due to elevated GH and IGF-I levels.3 The prevalence of acromegaly varies from 125 per 
million4 to 1034 per million5 depending on the patient identification criteria used in each study, indicating that 
this disease is not as rare as previously thought. Control of GH and IGF-I according to strict biochemical criteria, 
can return mortality of acromegalic patients to normal.2,3 Transsphenoidal neurosurgery is the primary treatment 
and long-acting SSA are the mainstay of medical treatment (primary or adjunctive) for acromegaly.6,7 
Presurgical SSA therapy can improve physical status and surgical success.8,9 SSA normalize GH and IGF-I in 
50-60% of cases and induce tumor shrinkage in about 40%.6,10,11 However, a sizable proportion of patients, 
mainly patients that are young or have large tumors, are incompletely responsive to current SSA.12 
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Somatostatin binds to a family of receptors (SSTR1-5), which belong to the 7-transmembrane-domain G-protein 
coupled receptors (GPCR13). The most commonly used SSA, octreotide and lanreotide, primarily bind to SSTR2 
and with less affinity to SSTR5. Somatostatin and its analogues exert their antiproliferative effects by causing 
cell cycle arrest14,15 and/or apoptosis.16 
In a previous study, we have demonstrated that octreotide mediates its antiproliferative action in a pituitary 
tumor cell model by inhibiting the PI3K/Akt survival pathway and inducing the expression of the tumor 
suppressor ZAC1/Zac1.17 ZAC1 is a zinc finger transcription factor highly expressed in the normal pituitary but 
downregulated in the majority of pituitary adenomas.18 Octreotide failed to suppress cell viability in pituitary 
tumor cells in which Zac1 was knocked-down, suggesting the importance of this factor in SSA antiproliferative 
action. This study was undertaken to assess whether ZAC1 expression levels in somatotropinomas were 
associated with hormonal and tumor shrinkage responses to SSA therapy in patients with acromegaly. 
Material and methods 
Patients 
The data for this study were drawn from the relational database, the Liège Acromegaly Survey (LAS, Graphmed, 
Liège, Belgium). The LAS contains data from patients with acromegaly treated at the Centre Hospitalier 
Universitaire, Liège, Belgium over the period 1970-2006. Among these patients, 123 consecutive patients 
received SSAs. Data from 75 patients were excluded from this study due to: lack of MRI scans at diagnosis and 
post-treatment (n = 33), lack of tumor sample (n = 18), primary medical therapy (n = 10), use of dopamine 
agonists (n = 8) and previous radiotherapy (n = 6). The initial study cohort comprised data from 48 patients. 
Acromegaly was diagnosed following the failure to suppress plasma GH to <2 µg/L during a 2 hr oral glucose 
tolerance test (OGTT), in addition to an elevated IGF-I level for age and sex. All 48 patients underwent 
transphenoidal neurosurgery; in 3 cases where patients underwent a second surgery for tumor re-growth, the 
second operative sample was studied. One patient had multiple endocrine neoplasia type 1 (MEN-1). 
Tumor characteristics 
Tumor samples from 48 patients were identified. Histopathological studies showed that 43 tumors stained 
positive for GH (24 GH alone, 16 mixed GH/prolactin and 3 plurihormonal). In 2 cases, no histopathological 
diagnosis was available. Three cases were histologically diagnosed as oncocytomas and were excluded from the 
study. Therefore, the final study cohort consisted of 45 patients. 
This study was approved by the ethics committee of the University of Liège. 
SSA treatment 
The mean duration of preoperative SSA therapy was 7.5 ± 6.2 months (range: 4-38 months). Three patients who 
underwent a second intervention had received SSAs only before the second intervention. Octreotide acetate s.c. 
(Sandostatin®, N.V. Novartis Pharma S.A., Vilvoorde, Belgium) was used in 26 patients (dose: 300-1500 
mg/day), and 2 patients received octreotide LAR (dose: 20-30 mg/28 days). In the patients receiving intermittent 
s.c. octreotide, treatment was discontinued 1-4 days before surgery, while those treated with octreotide LAR, the 
final dose was given less than a month before surgery. Fourteen patients received 20-30 mg of long acting 
lanreotide (Somatuline LA®, Ipsen NV, Merelbeke, Belgium) every 10-14 days and treatment was ceased ~10 
days before surgery; 3 others received lanreotide Autogel (dose: 60-120 mg/28 days) and treatment stopped less 
than a month before surgery. 
GH and IGF-I measurements 
GH and IGF-I levels were determined at diagnosis (following a 2 hr OGTT) and the last value at the end of 
preoperative SSA therapy, before the patient underwent surgery. The cut-off value for normalization of GH was 
≤2.0 µg/L. Because of the variety of assays used over time, IGF-I data were expressed for each assay as a 
percentage of the upper limit of normal (ULN) values for age and sex. Thus, the cut-off value for normalization 
of IGF-I was 100%. 
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Radiological data 
Tumor size was evaluated by MRI at the time of diagnosis and after preoperative SSA therapy. Changes in tumor 
size were classified as no change or shrinkage (≥15% decrease in maximum diameter). All the images were 
viewed by the same experienced neuroradiologist and changes in tumor size were verified independently by a 
second experienced reviewer. The cut-off of 15% was chosen in accordance with criteria used in previous 
studies.7,8 
ZAC1 immunohistochemistry 
For ZAC1 determination, 4 µm paraffin sections of tumor samples were used. Antigen retrieval was performed 
by microwave heating for 15 min in 10 mM citrate buffer at a pH of 6.0. ZAC1 immunohistochemistry was 
performed as previously described18 and immunoreactivity was determined by 2 independent investigators. The 
ZAC1 staining intensity pattern was classified as: weak (+), moderate (+ +) and strong (+ + +). A normal human 
pituitary from an autopsy case taken 12 hr after sudden death (no evidence of a pituitary adenoma or other 
endocrine disease) was used as a positive control. For negative controls, the primary antibody was omitted. 
Statistics 
Statistical analysis was performed using SPSS version 15.0 (SPSS, Chicago, IL). Tumors were classified into 3 
groups according to their ZAC1 immunoreactivity (+ , ++ and + + +, respectively). The response to SSAs in 
terms of GH was classified as 1 (≤2.0 µg/L) or 0 (no normalization). The response to SSAs in terms of IGF-I was 
classified as 1 (≤100% of the ULN for age and sex) or 0 (>100% of the ULN for age and sex). Changes in tumor 
size were classified as 0 (no change) or 1 (shrinkage; ≥15% decrease in maximum diameter). Tumor histology 
was classified as 0 (GH only), 1 (mixed GH-PRL) and 2 (plurihormonal). 
Fisher's exact test with chi-square statistics and Spearman rank test were used to assess the homogeneity of the 
frequency distribution of discrete or nominal parameters within the ZAC1 immunoreactivity groups. 
Associations between these parameters and ZAC1 immunoreactivity were confirmed using Somer's D-test. For 
continuous parameters, differences in their means between the 3 ZAC1 groups were tested for significance by 
analysis of variance (ANOVA). The p < 0.05 was considered to be statistically significant. 
 
TABLE I - PATIENT CHARACTERISTICS OF THE STUDY COHORT 
Variables  % 
Demographics   
Male 24 53.3 
Female 21 46.7 
Mean age at diagnosis, year (SD) 45.8 (12.8)  
Histology   
GH 24 53.3 
Mixed GH/PRL 16 35.6 
Plurihormonal 3 6.7 
Unknown 2 4.4 
Baseline laboratory values (diagnosis)   
Mean GH µg/L (SD) 29.3 (±29.2)  
MeanIGF-1%(SD) 226.1 (±107.8)  
Tumor shrinkage   
No 21 46.7 
Yes 24 53.3 
GH normalization   
No 23 51.1 
Yes 22 48.9 
IGF-1 normalization   
No 21 46.7 
Yes 24 53.3 
SD, standard deviation. 
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Results 
Patient characteristics are shown in Table I. There were 24 men and 21 women; the mean age at diagnosis was 
46.8 ± 12.6 years (range 18-67 years). The mean baseline GH level in the study group was 29.3 µg/L and the 
mean baseline IGF-I was 226.1% of the ULN for age and sex. Tumor shrinkage occurred with SSA therapy in 
53.3% of cases; GH and IGF-I normalization was seen in 48.9% (22/45) and 53.3% (24/45) cases, respectively. 
All tumors displayed nuclear ZAC1 immunoreactivity, which varied in intensity across weak (+ ; n = 15), 
moderate (+ +; n = 16) and strong (+ + + ; n = 14) groups (examples of each intensity are displayed in Fig. 1). 
Characteristics of the different ZAC1 immunostaining groups are shown in Table II. None of the acromegalic 
tumors examined were found negative for ZAC1, and the intensity of ZAC1 immunoreactivity was assessed 
against patient's characteristics and SSA treatment outcome. 
Associations with ZAC1 immunoreactivity 
Age and gender. The intensity of ZAC1 immunoreactivity was not related with gender (Fisher's exact test: p = 
0.3865) or age at diagnosis (ANOVA: p = 0.967). 
GH and IGF-I 
A significant association existed between ZAC1 expression and normalization of IGF-I levels (Fisher's exact 
test, p = 0.0027; Fig. 2). This correlation was confirmed using Spearman rank test (r = 0.517, p < 0.0001) and 
Somer's D-test (D = 0.56, p = 0.0005). Tumors with moderate ZAC1 immunoreactivity show a higher probability 
to respond to SSA compared with "weak" tumors, but not as high as "strong" tumors (Fig. 2b). No association 
was seen between ZAC1 and GH normalization (Fisher's exact test: p = 0.36; Spearman rank test: r = 0.0019, p = 
0.99; Somer's D-test: D = 0.002, p = 1.000). 
Tumor shrinkage 
Tumor shrinkage after SSA treatment was significantly associated with ZAC1 expression (Fisher's exact test, p = 
0.0028; Somer's D-test D = 0.52, p = 0.0011), which was confirmed using the Spearman rank test (r = 0.476, p 
= 0.001). Tumors with moderate ZAC1 immunoreactivity were found to correlate similarly with those having 
strong ZAC1 immunoreactivity in terms of tumor shrinkage (Table II). 
Other parameters 
ZAC1 expression did not correlate with tumor histology (Fisher's exact test: p = 0.68), initial GH (p = 0.97), 












Published in : International Journal of Cancer = Journal International du Cancer (2009), vol. 125, pp. 2122-2126 
Status : Postprint (Author’s version) 
 
TABLE II - PATIENT CHARACTERISTICS ACCORDING TO ZAC1 IMMUNOREACTIVITY: WEAK, 









p-values D and p-values r/p3 
Total 15 16 14    
Gender       
Female 8 9 4 0.38650 D = 0.18634.  
Male 7 7 10  p = 0.2981  
Histology       
GH 8 7 8 0.68498 D = 0.06034. r = 0.05972. 
Mixed 6 6 4  p = 0.6906 p = 0.7151 
Other  2 2    
n.a. 1 1     
Tumor shrinkage       
Yes 2 11 10 0.0028 D = 0.52193. r = 0.47663. 
No 13 4 4  p = 0.0011 p = 0.0010 
GH normalization       
Yes (≤2.0) 6 10 6 0.36034 D = 0.00207. r = 0.00193. 
No 9 6 8  p = 1.0000 p = 0.9902 
IGF-I normalization       
Yes 3 9 12 0.0027 D = 0.56315. r = 0.51740. 
No 12 7 2  p = 0.0005 p < 0.0001 
    p-values ANOVA F-values 
DF: 2, 42 
 
Age at diagnosis 46.33 ± 12.9 46.63 ± 13.99 47.15 ± 11.49 0.967 0.103  
Treatment duration 6.20 ± 2.60 6.19 ± 2.26 10.07 ± 10.68 0.094 2.409  
Initial GH 30.64 ± 30.07 30.35 ± 34.19 26.54 ± 23.67 0.975 0.089  
Initial IGF-I 217.43 ± 74.92 239.00 ± 90.47 220.62 ± 154.20 0.871 0.364  
∆-GH 22.30 ± 27.32 21.87 ± 24.89 18.84 ± 16.25 0.961 0.071  
∆-IGF-I 64.29 ± 106.44 60.27 ± 128.31 144.31 ± 154.06 0.150 1.498  
The statistical correlation between patient characteristic and ZAC1 immunoreactivity is shown as Fisher's exact probability test (p), 
Sommer's D-test (D and p) and Spearman's rank correlation coefficient (r/p). DF, degree of freedom; n.a., not available. 1Fisher's Exact test.-
2Somer's D-test.-3Spearman's test. 
 
 
Figure 1 - ZAC1 immunoreactivity in archival paraffin-embedded acromegalic tumors. In the figure are 
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Figure 2 - (a) Graph showing the distribution of the individual final IGF-I values, determined after completion 
of SSA treatment and before surgery, among the 3 groups of ZAC1 immunoreactivity. IGF-I values are expressed 
as a percentage of the upper limit of normal (ULN) values for age and sex. The cut-off value for normalization of 




ZAC1/Zac1 (also known as LOT1 and PLAGL1) is a zinc finger transcription factor that can induce apoptosis 
and cell cycle arrest and plays an important role in embryonic growth by regulating genes such as igf2 and 
p57kip2 (Cdkn1c19,20). ZAC1/Zac1 is highly expressed in the murine and human anterior pituitary, but is 
downregulated in the majority of pituitary adenoma subtypes. Eliminating Zac1 expression using antisense 
techniques increased cell proliferation in murine pituitary tumor cell lines. We recently showed that Zac1 acts 
downstream of SSTR2. Rat pituitary tumor cells, in which Zac1 was knocked-down by RNA interference, were 
resistant to octreotide's antiproliferative action. These data highlight ZAC1/Zac1 as an important component of 
the antiprohferative action of octreotide. 
In this study, we examined whether ZAC1 immunoreactivity was related to the response to SSAs in patients with 
acromegaly. ZAC1 expression did not correlate with age and gender confirming our previous findings.18 ZAC1 
expression positively correlated with IGF-I normalization, but not with GH normalization. Nevertheless, a 
divergent profile in terms of GH and IGF-I control is well recognized to occur in the setting of SSA treatment.6 
The reasons for the divergent results in this study may be similarly due to the difficulties in assessing true 
integrated 24-hr GH secretion due to the inherent pulsatility of GH. Also, ultrasensitive GH assays show that GH 
levels can be < 1.0 µg/L after OGTT in the setting of active acromegaly. The retrospective nature of this study 
meant that ultrasensitive GH assays were not uniformly available in all patients, and together these issues may 
have contributed to discordant results. 
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Interestingly, there was a positive correlation between increased ZAC1 immunoreactivity and tumor shrinkage 
after SSA therapy. ZAC1 immunoreactivity did not correlate with other patient characteristics, such as baseline 
IGF-I, baseline GH and the duration of SSA treatment. Tumor shrinkage is reported in 40-50% of acromegalic 
patients receiving SSA treatment.22,23 Although tumor shrinkage is a recognized effect of SSAs, the molecular 
mechanisms behind it have yet to be elucidated.12 
SSAs were shown to inhibit cell cycle progression in vitro.15,16 Reduced Ki-67 protein levels in tumors from 
acromegalic patients treated with octreotide supports the concept that SSAs induce cell cycle arrest in vivo.24 
Somatostatin was also shown to induce apo-ptosis, mainly through SSTR3,25 although there is evidence for the 
involvement of SSTR2.26 However, apoptosis was not significantly increased in octreotide-treated tumors. 
Furthermore no necrotic events, or other morphological changes, were found in SSA treated acromegalic 
tumors.27 These reported data suggest that SSA-induced tumor shrinkage is probably due to cell growth arrest 
rather than apoptosis. ZAC1/Zac1 limits cell growth by inducing cell cycle arrest19; therefore it can cause, at 
least in part, the cell cycle arrest state reported in acromegalic tumors after SSA treatment (reviewed in Ref. 23). 
The positive correlation between ZAC1 immunoreactivity and tumor shrinkage and decreased IGF-I levels after 
SSA treatment, suggest ZAC1 as a possible marker for SSA response. A reliable immunohistopafhological 
marker could help to guide treatment in patients with residual tumor postoperatively toward either long-term 
adjuvant SSA or consideration of re-operation to debulk the remaining tumor, which we and others have shown 
to significantly increase subsequent control with SSAs.22,28 Previous studies have shown that somatotroph tumor 
type can predict SSA treatment outcome, with densely granulated adenomas having a higher probability to 
respond to this treatment than sparsely granulated.2 Furthermore, the expression of the α-subunit of the 
heterotrimeric GTP-binding protein Gsα was found to be higher in octreotide-sensitive acromegalic tumors.29 In 
addition, the expression of the different SSTR types in responders versus nonresponders was also a subject of 
intense investigation. Positive SSTR autoradiography/scintigraphy correlated with octreotide's therapeutic 
efficacy.30-32 Furthermore, low SSTR2 expression was associated with poor hormonal response after SSA 
treatment33,34 and this was confirmed at protein level by finding a strong correlation between SSTR2A 
immunoreactivity and GH decrease after an octreotide suppression test.35 Indeed SSTR2 gene transfer to 
partially SSA resistant human somatotroph tumors in primary cell culture increased their response to octreotide 
treatment.36 In addition, a mutation in SSTR5 was found in 1 acromegalic patient resistant to octreotide 
treatment.37 
In summary, ZAC1 immunostaining on tumor tissue was associated with tumor shrinkage and IGF-I 
normalization in patients with acromegaly treated with SSAs. Considering that ZAC1 is a tumor suppressor gene 
that plays a prominent role in the antiproliferative action of SSA, these data suggest a mechanistic role for this 
factor in SSA-induced tumor shrinkage and general treatment response. Zac1 was shown to be downstreams to 
the PI3K/Akt pathway, which plays a central role in the regulation of cell survival and growth.17 Whether 
ZAC1/Zac1 inhibits this pathway at transcriptional level to mediate SSA-induced tumor shrinkage is an issue 
that deserves further study. In addition our findings of a correlation between high ZAC1 immunoreactivity and 
IGF-I normalization suggests the possibility of a putative role for this transcription factor on SSA dependent 
decrease in hormone synthesis. The herein reported in vivo study points to a central role for ZAC1 in SSA action 
and raises several issues, the elucidation of which will facilitate the better understanding of SSA action and will 
subsequently lead to improvements in SSA treatment efficacy. 
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